Perforation of the Colon During Imatinib Mesylate (Gleevec) Treatment in a Patient with Chronic Myeloid Leukemia (CML)
نویسندگان
چکیده
منابع مشابه
Perforation of the Colon During Imatinib Mesylate (Gleevec) Treatment in a Patient with Chronic Myeloid Leukemia (CML)
Imatinib (Gleevec; STI-571) is a tyrosine-kinase inhibitor (TKI) used in the treatment of multiple cancers, most notably Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) as well as gastrointestinal stromal tumor (GIST). The most common adverse effects with imatinib include superficial edema, muscle cramps, musculoskeletal pain, rash, fatigue, headache, and gastrointesti...
متن کاملHematopathology / IMATINIB MESYLATE (GLEEVEC) FOR CHRONIC MYELOID LEUKEMIA Chronic Myeloid Leukemia Following Therapy With Imatinib Mesylate (Gleevec) Bone Marrow Histopathology and Correlation With Genetic Status
We evaluated bone marrow pathologic features and cytogenetic and molecular genetic status of 13 patients with interferon-resistant, chronic-phase chronic myeloid leukemia (CML), treated with imatinib mesylate (Gleevec). All had morphologic evidence of CML in the blood and bone marrow and were positive for bcr-abl by reverse transcriptase–polymerase chain reaction, fluorescence in situ hybridiza...
متن کاملAnalysis of Expression Of SIRT1 Gene In Patients With Chronic Myeloid Leukemia Resistant To Imatinib Mesylate
Background: Chronic myeloid leukemia is a clonal myeloproliferative disease which is characterized by bcr/abl translocation. With the emergence of tyrosine kinase inhibitors such as imatinib mesylate, significant improvement has been made in treatment of this disease. However, drug resistance against this medicine is still an obstacle. SIRT1 is a gene with deacetylase activity which has been de...
متن کاملDevelopment of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate.
The Oncologist 2005;10:457–458 www.TheOncologist.com The co-occurrence of chronic myeloid leukemia (CML) and multiple myeloma (MM) is an extremely rare event and is considered to be coincidental [1, 2]. Imatinib mesylate (Gleevec®; Novartis Pharmaceuticals Corporation, East Hanover, NJ, http://www.pharma.us.novartis.com) is the new gold standard for the treatment of CML, particularly in patient...
متن کاملNovel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
Imatinib mesylate (Gleevec) was developed as the first molecularly targeted therapy that specifically inhibits the BCR-ABL tyrosine kinase activity in patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML). Due to its excellent hematologic and cytogenetic responses, particularly in patients with chronic phase CML, imatinib has moved towards first-line treatment for ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cureus
سال: 2016
ISSN: 2168-8184
DOI: 10.7759/cureus.660